Extensive Stage Lung Small Cell CarcinomaPhase 3NCT04155034
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
A Phase 3 study testing Magnetic Resonance Imaging and Prophylactic Cranial Irradiation in people with Extensive Stage Lung Small Cell Carcinoma and Limited Stage Lung Small Cell Carcinoma, run by SWOG Cancer Research Network at 446 sites in 7 countries.
Trial summary
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
- What is being tested?
- Magnetic Resonance Imaging and Prophylactic Cranial Irradiation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 668 participants
- Where
- 446 sitesin 7 countries
- Study dates
- 4 May 2020to 15 Nov 2029
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC)
- Patient must have an MRI of the brain performed within 28 days prior to registration documenting no evidence of brain metastases or leptomeningeal disease. Patient also must not have a history of brain metastases or leptomeningeal disease
- Immunotherapy concurrent with and/or adjuvant to first-line therapy is allowed at the discretion of the treating physician. Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including stereotactic body radiation therapy [SBRT] for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the treating physician, but is not required. Patients with extensive-stage (ES)-SCLC must have completed platinum-based chemotherapy either with or without thoracic radiotherapy at the discretion of the treating physician
- All adverse events from prior treatment must have resolved to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) prior to randomization
- Patient must have had a response to first-line therapy and no evidence of progression in opinion of the treating investigator. Systemic imaging (computed tomography [CT] or positron emission tomography [PET]/CT including the chest and abdomen) must be performed within 28 days prior to randomization
- No more than 8 weeks may have elapsed between day 1 of the last cycle of chemotherapy and randomization
Show all 25Show fewer
- Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patients who have undergone prior stereotactic radiosurgery for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis
- Patient must have Zubrod performance status of 0-2
- Patient must not have a contraindication to MR imaging, such as implanted metal devices or foreign bodies
- Patient must not have a contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
- Patient must not have other metastatic malignancies requiring current active treatment
- Patient must not have any severe active comorbidities, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to randomization
- Transmural myocardial infarction within 6 months prior to randomization
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization
- Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of randomization
- Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease
- Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter
- Note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 16 weeks prior to randomization
- Note also that HIV testing is not required for eligibility for this protocol
- Patient must not be pregnant because of fetal risks from radiation exposure. Men must have agreed to use an effective contraceptive method during PCI and for six months after completing PCI. Women of reproductive potential must have agreed to use an effective contraceptive method during PCI. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Patients who speak and understand English or French must agree to participate in cognitive function testing
- Patient must be offered the opportunity to have specimens submitted for banking
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As a part of the Oncology Patient Enrollment Network (OPEN) randomization process the treating institution?s identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Who cannot join
None listed.
Trial locations and contacts
446 sites in 7 countries.
318 sites in 7 countries
United States300 sites
Hawaii Cancer Care - Westridge
‘Aiea, Hawaii, 96701
Pali Momi Medical Center
‘Aiea, Hawaii, 96701
The Cancer Center of Hawaii-Pali Momi
‘Aiea, Hawaii, 96701
Cleveland Clinic Akron General
Akron, Ohio, 44307
Atrium Health Stanly/LCI-Albemarle
Albemarle, North Carolina, 28002
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87106
Lovelace Radiation Oncology
Albuquerque, New Mexico, 87109
Northside Hospital-Alpharetta
Alpharetta, Georgia, 30005
Alton Memorial Hospital
Alton, Illinois, 62002
OSF Saint Anthony's Health Center
Alton, Illinois, 62002
McFarland Clinic - Ames
Ames, Iowa, 50010
Katmai Oncology Group
Anchorage, Alaska, 99508
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, 48106
Luminis Health Anne Arundel Medical Center
Annapolis, Maryland, 21401
Langlade Hospital and Cancer Center
Antigo, Wisconsin, 54409
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
ThedaCare Regional Medical Center - Appleton
Appleton, Wisconsin, 54911
Northwest Wisconsin Cancer Center
Ashland, Wisconsin, 54806
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322
Northside Hospital
Atlanta, Georgia, 30342
John Fitzgerald Kennedy Medical Center
Atlantis, Florida, 33462
Augusta University Medical Center
Augusta, Georgia, 30912
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, 80045
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045
IU Health West Hospital
Avon, Indiana, 46123
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
Veterans Administration Medical Center-Baltimore
Baltimore, Maryland, 21201
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Advocate Good Shepherd Hospital
Barrington, Illinois, 60010
MaineHealth Coastal Cancer Treatment Center
Bath, Maine, 04530
UHHS-Chagrin Highlands Medical Center
Beachwood, Ohio, 44122
UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania, 15009
UM Upper Chesapeake Medical Center
Bel Air, Maryland, 21014
Sanford Joe Lueken Cancer Center
Bemidji, Minnesota, 56601
ThedaCare Cancer Care - Berlin
Berlin, Wisconsin, 54923
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Billings Clinic Cancer Center
Billings, Montana, 59101
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Saint Joseph's/Candler - Bluffton Campus
Bluffton, South Carolina, 29910
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Boston Medical Center
Boston, Massachusetts, 02118
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Lafayette Family Cancer Center-EMMC
Brewer, Maine, 04412
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton, Michigan, 48114
Trinity Health Medical Center - Brighton
Brighton, Michigan, 48114
Crozer-Keystone Regional Cancer Center at Broomall
Broomall, Pennsylvania, 19008
Henry Ford Cancer Institute-Downriver
Brownstown, Michigan, 48183
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Roswell Park Cancer Institute
Buffalo, New York, 14263
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Hematology Oncology Associates of CNY at Camillus
Camillus, New York, 13031
Sands Cancer Center
Canandiaqua, New York, 14424
Northside Hospital-Cherokee
Canton, Georgia, 30115
Trinity Health Medical Center - Canton
Canton, Michigan, 48188
Cleveland Clinic Mercy Hospital
Canton, Ohio, 44708
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Carlisle Regional Cancer Center
Carlisle, Pennsylvania, 17015
IU Health North Hospital
Carmel, Indiana, 46032
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Miami Valley Hospital South
Centerville, Ohio, 45459
Centralia Oncology Clinic
Centralia, Illinois, 62801
Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania, 19317
Chambersburg Hospital
Chambersburg, Pennsylvania, 17201
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Atrium Health Pineville/LCI-Pineville
Charlotte, North Carolina, 28210
Atrium Health University City/LCI-University
Charlotte, North Carolina, 28262
Chelsea Hospital
Chelsea, Michigan, 48118
Northwestern University
Chicago, Illinois, 60611
Rush University Medical Center
Chicago, Illinois, 60612
University of Illinois
Chicago, Illinois, 60612
University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio, 45219
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376
Morton Plant Hospital
Clearwater, Florida, 33756
Case Western Reserve University
Cleveland, Ohio, 44106
Louis Stokes Cleveland VA Medical Center
Cleveland, Ohio, 44106
Mercy Cancer Center-West Lakes
Clive, Iowa, 50325
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa, 50325
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Baptist Memorial Hospital and Cancer Center-Collierville
Collierville, Tennessee, 38017
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909
Memorial Hospital North
Colorado Springs, Colorado, 80920
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, 21044
MU Health - University Hospital/Ellis Fischel Cancer Center
Columbia, Missouri, 65212
John B Amos Cancer Center
Columbus, Georgia, 31904
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Riverside Methodist Hospital
Columbus, Ohio, 43214
Grant Medical Center
Columbus, Ohio, 43215
Doctors Hospital
Columbus, Ohio, 43228
Atrium Health Cabarrus/LCI-Concord
Concord, North Carolina, 28025
MD Anderson in The Woodlands
Conroe, Texas, 77384
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida, 33146
City of Hope Corona
Corona, California, 92882
Greater Regional Medical Center
Creston, Iowa, 50801
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141
Northwest Cancer Center - Main Campus
Crown Point, Indiana, 46307
AMG Crystal Lake - Oncology
Crystal Lake, Illinois, 60014
Northside Hospital-Forsyth
Cumming, Georgia, 30041
Carle at The Riverfront
Danville, Illinois, 61832
Geisinger Medical Center
Danville, Pennsylvania, 17822
Premier Blood and Cancer Center
Dayton, Ohio, 45409
Miami Valley Hospital North
Dayton, Ohio, 45415
Corewell Health Dearborn Hospital
Dearborn, Michigan, 48124
Atlanta VA Medical Center
Decatur, Georgia, 30033
Cancer Care Specialists of Illinois - Decatur
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida, 33442
Delaware Health Center-Grady Cancer Center
Delaware, Ohio, 43015
Grady Memorial Hospital
Delaware, Ohio, 43015
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
UI Health Care Mission Cancer and Blood - Des Moines Clinic
Des Moines, Iowa, 50309
Broadlawns Medical Center
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
UI Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Henry Ford Hospital
Detroit, Michigan, 48202
Henry Ford Health Saint John Hospital
Detroit, Michigan, 48236
Advocate Good Samaritan Hospital
Downers Grove, Illinois, 60515
City of Hope Comprehensive Cancer Center
Duarte, California, 91010
Dublin Methodist Hospital
Dublin, Ohio, 43016
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Durham VA Medical Center
Durham, North Carolina, 27705
Northwest Oncology LLC
Dyer, Indiana, 46311
Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
East Norriton, Pennsylvania, 19401
Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
University of Maryland Shore Medical Center at Easton
Easton, Maryland, 21601
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin, 54701
Saint Elizabeth Healthcare Edgewood
Edgewood, Kentucky, 41017
Carle Physician Group-Effingham
Effingham, Illinois, 62401
Crossroads Cancer Center
Effingham, Illinois, 62401
Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus
Elizabeth, New Jersey, 07207
Ephrata Cancer Center
Ephrata, Pennsylvania, 17522
UPMC Hillman Cancer Center Erie
Erie, Pennsylvania, 16505
Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Parkland Health Center - Farmington
Farmington, Missouri, 63640
Farmington Health Center
Farmington, Utah, 84025
Corewell Health Farmington Hills Hospital
Farmington Hills, Michigan, 48336
UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania, 16121
Augusta Health Center for Cancer and Blood Disorders
Fishersville, Virginia, 22939
Levine Cancer Institute - Rutherford
Forest City, North Carolina, 28043
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado, 80528
Saint Elizabeth Healthcare Fort Thomas
Fort Thomas, Kentucky, 41075
Atrium Medical Center-Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fox Chase Cancer Center Buckingham
Furlong, Pennsylvania, 18925
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
UM Baltimore Washington Medical Center/Tate Cancer Center
Glen Burnie, Maryland, 21061
Crozer Regional Cancer Center at Brinton Lake
Glen Mills, Pennsylvania, 19342
Glens Falls Hospital
Glens Falls, New York, 12801
Aurora Cancer Care-Grafton
Grafton, Wisconsin, 53024
Altru Cancer Center
Grand Forks, North Dakota, 58201
Benefis Sletten Cancer Institute
Great Falls, Montana, 59405
Banner North Colorado Medical Center
Greeley, Colorado, 80631
UCHealth Greeley Hospital
Greeley, Colorado, 80631
Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania, 15601
Miami Valley Cancer Care and Infusion
Greenville, Ohio, 45331
Saint Francis Hospital
Greenville, South Carolina, 29601
Saint Francis Cancer Center
Greenville, South Carolina, 29607
Smilow Cancer Hospital Care Center at Greenwich
Greenwich, Connecticut, 06830
Self Regional Healthcare
Greenwood, South Carolina, 29646
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Mount Carmel Grove City Hospital
Grove City, Ohio, 43123
Smilow Cancer Hospital Care Center - Guilford
Guilford, Connecticut, 06437
Smilow Cancer Hospital-Hamden Care Center
Hamden, Connecticut, 06518
The Cancer Institute of New Jersey Hamilton
Hamilton, New Jersey, 08690
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania, 17109
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado, 80129
The Radiation Oncology Center-Hilton Head/Bluffton
Hilton Head Island, South Carolina, 29926
Edward Hines Jr VA Hospital
Hines, Illinois, 60141
Northwest Cancer Center - Hobart
Hobart, Indiana, 46342
Saint Mary Medical Center
Hobart, Indiana, 46342
Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii, 96813
Queen's Cancer Cenrer - POB I
Honolulu, Hawaii, 96813
Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital
Honolulu, Hawaii, 96813
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813
Kuakini Medical Center
Honolulu, Hawaii, 96817
Queen's Cancer Center - Kuakini
Honolulu, Hawaii, 96817
The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii, 96817
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
M D Anderson Cancer Center
Houston, Texas, 77030
Michael E DeBakey VA Medical Center
Houston, Texas, 77030
MD Anderson West Houston
Houston, Texas, 77079
Novant Health Cancer Institute - Huntersville
Huntersville, North Carolina, 28078
Novant Health Presbyterian Medical Center Huntersville
Huntersville, North Carolina, 28078
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202
IU Health Methodist Hospital
Indianapolis, Indiana, 46202
MU Health Care Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania, 15901
Freeman Health System
Joplin, Missouri, 64804
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Logan Health Medical Center
Kalispell, Montana, 59901
University of Kansas Cancer Center
Kansas City, Kansas, 66160
University of Kansas Cancer Center - North
Kansas City, Missouri, 64154
Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin, 53142
Novant Health Cancer Institute - Kernersville
Kernersville, North Carolina, 27284
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Marshfield Medical Center - Ladysmith
Ladysmith, Wisconsin, 54848
Saint Anthony Hospital
Lakewood, Colorado, 80228
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
MD Anderson League City
League City, Texas, 77573
Sechler Family Cancer Center
Lebanon, Pennsylvania, 17042
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri, 64064
Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania, 17837
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536
Cancer Partners of Nebraska
Lincoln, Nebraska, 68516
CaroMont Health - Lincoln Cancer Center
Lincolnton, North Carolina, 28092
Trinity Health Saint Mary Mercy Livonia Hospital
Livonia, Michigan, 48154
Veterans Affairs Loma Linda Healthcare System
Loma Linda, California, 92357
Tibor Rubin VA Medical Center
Long Beach, California, 90822
Monmouth Medical Center
Long Branch, New Jersey, 07740
Los Angeles General Medical Center
Los Angeles, California, 90033
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky, 40202
UofL Health Medical Center Northeast
Louisville, Kentucky, 40245
Medical Center of the Rockies
Loveland, Colorado, 80538
Banner McKee Medical Center
Loveland, Colorado, 80539
OhioHealth Mansfield Hospital
Mansfield, Ohio, 44903
Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin, 54143
OhioHealth Marion General Hospital
Marion, Ohio, 43302
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, 54449
Matthews Radiation Oncology Center
Matthews, North Carolina, 28105
Novant Health Cancer Institute - Matthews
Matthews, North Carolina, 28105
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois, 61938
Loyola University Medical Center
Maywood, Illinois, 60153
UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania, 15132
UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
Mechanicsburg, Pennsylvania, 17050
Riddle Memorial Hospital
Media, Pennsylvania, 19063
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Froedtert Menomonee Falls Hospital
Menomonee Falls, Wisconsin, 53051
UH Seidman Cancer Center at Lake Health Mentor Campus
Mentor, Ohio, 44060
East Jefferson General Hospital
Metairie, Louisiana, 70006
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
UH Seidman Cancer Center at Southwest General Hospital
Middleburg Heights, Ohio, 44130
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional
Milford, Massachusetts, 01757
Beebe South Coastal Health Campus
Millville, Delaware, 19967
Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin, 53209
Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Aurora Sinai Medical Center
Milwaukee, Wisconsin, 53233
Zablocki Veterans Administration Medical Center
Milwaukee, Wisconsin, 53295
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Marshfield Medical Center - Minocqua
Minocqua, Wisconsin, 54548
Atrium Health Union/LCI-Union
Monroe, North Carolina, 28112
UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania, 15146
UPMC Hillman Cancer Center in Coraopolis
Moon Township, Pennsylvania, 15108
Novant Health Cancer Institute - Mooresville
Mooresville, North Carolina, 28117
West Virginia University Healthcare
Morgantown, West Virginia, 26506
Novant Health Cancer Institute - Mount Airy
Mount Airy, North Carolina, 27030
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149
The Community Hospital
Munster, Indiana, 46321
Women's Diagnostic Center - Munster
Munster, Indiana, 46321
ThedaCare Regional Medical Center - Neenah
Neenah, Wisconsin, 54956
CarolinaEast Medical Center
New Bern, North Carolina, 28561
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Yale University
New Haven, Connecticut, 06520
ThedaCare Cancer Care - New London
New London, Wisconsin, 54961
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112
University Medical Center New Orleans
New Orleans, Louisiana, 70112
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Helen F Graham Cancer Center
Newark, Delaware, 19713
Medical Oncology Hematology Consultants PA
Newark, Delaware, 19713
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
CTCA at Southeastern Regional Medical Center
Newnan, Georgia, 30265
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri, 64116
Novant Health Cancer Institute - Wilkesboro
North Wilkesboro, North Carolina, 28659
Cancer Care Center of O'Fallon
O'Fallon, Illinois, 62269
HSHS Saint Elizabeth's Hospital
O'Fallon, Illinois, 62269
Drexel Town Square Health Center
Oak Creek, Wisconsin, 53154
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453-2699
TidalHealth Richard A Henson Cancer Institute
Ocean Pines, Maryland, 21811
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Nebraska Methodist Hospital
Omaha, Nebraska, 68114
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
ThedaCare Cancer Care - Oshkosh
Oshkosh, Wisconsin, 54904
Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin, 54904
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas, 66210
Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi, 38655
Paoli Memorial Hospital
Paoli, Pennsylvania, 19301
Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068
Camden Clark Medical Center
Parkersburg, West Virginia, 26101
University Hospitals Parma Medical Center
Parma, Ohio, 44129
Capital Health Medical Center-Hopewell
Pennington, New Jersey, 08534
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Mercy Health - Perrysburg Hospital
Perrysburg, Ohio, 43551
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Temple University Hospital
Philadelphia, Pennsylvania, 19140
Canada13 sites
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2
The Research Institute of the McGill University Health Centre (MUHC)
Montreal, Quebec, H3H 2R9
Lakeridge Health Oshawa
Oshawa, Ontario, L1G 2B9
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Atlantic Health Sciences Corporation-Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Sherbrooke, Quebec, J1H 5N4
Doctor H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, A1B 3V6
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
Centre Hospitalier Regional de Trois-Rivieres
Trois-Rivières, Quebec, G8Z 3R9
BCCA-Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 6V5
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Mexico1 site
Instituto Nacional De Cancerologia de Mexico
Mexico City, Tlalpan, 14080
Saudi Arabia1 site
King Faisal Specialist Hospital and Research Centre
Riyadh, 11211
South Korea1 site
National Cancer Center-Korea
Goyang-si, Gyeonggi-do, 410-769
About this study
Official title: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Read the detailed description
PRIMARY OBJECTIVE:
- To evaluate whether overall survival (OS) with magnetic resonance imaging (MRI) surveillance alone is not inferior to MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).
SECONDARY OBJECTIVES:
- To compare cognitive failure free survival (CFFS) rate up to 12 months after randomization between the arms.
II. To compare brain-metastasis-free survival between the arms. III. To compare OS between the arms within the subgroups of patients with limited-stage and extensive-stage disease.
IV. To compare cognitive failure free survival (CFFS) rates at the assessment times between the arms.
- To compare the cumulative incidence of cognitive failure with death as a competing risk between the arms.
VI. To compare the frequency and severity of toxicities between the two arms.
ADDITIONAL OBJECTIVE:
- To collect blood for banking.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
ARM II: Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
- Being tested
- Magnetic Resonance Imaging, Prophylactic Cranial Irradiation
- Medical subject headings
- Small Cell Lung Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance ImagingProcedure or surgery
Also called Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI
Undergo MRI
Prophylactic Cranial IrradiationRadiation
Also called PCI
Undergo PCI
| Study group | Role | What they receive |
|---|---|---|
| Arm I (PCI, MRI) | Active comparator | Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months. Receives: Procedure: Magnetic Resonance Imaging; Radiation: Prophylactic Cranial Irradiation |
| Arm II (MRI) | Experimental | Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months. Receives: Procedure: Magnetic Resonance Imaging |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival (OS)
Will evaluate OS with magnetic resonance imaging (MRI) surveillance alone and MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).
Measured: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization
Secondary outcomes (6)
Cognitive failure-free survival (CFFS)
The comparison of CFFS up to 12 months between the arms will be done using a 1-sided 5% level log-rank test.
Measured: Baseline to first neurocognitive failure CF or death due to any cause, assessed up to 12 months after randomization
CFFS rate
There will be a comparison of the CFFS rates between the arms at each of the assessment times and the cumulative incidence of cognitive failure, evaluating death as a competing risk. The CFFS rates at the landmark times will be estimated using the method of Kaplan-Meier and the difference in rates will be evaluated using a 90% confidence interval using Greenwood?s formula.
Measured: Baseline to first neurocognitive failure CF or death due to any cause, assessed at 90, 180, 270, 360, 540, and 720 days after randomization
Cumulative incidence of cognitive failure
The cumulative incidence of cognitive failure in the presence of the competing risk of death will be estimated used the method of Fine and Gray.
Measured: Neurocognitive function test will be assessed at 90, 180, 270, 360, 540, and 720 days after randomization
OS in an "as-treated" analysis
The comparison of OS in the ?as-treated? analysis will be done as described for the primary analysis, however patients will be categorized per treatment received (patients who do not accept their randomized assignment will be analyzed per treatment received). The number of patients not accepting the randomized assignment will also be summarized.
Measured: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization. Patients will be seen at day 90, 180, 270, 360, 540, and 720
Brain metastases-free survival (BMFS)
This will be estimated using the method of Kaplan-Meier and comparisons will be done using a log-rank test at the 1-sided 0.05 level. Hazard ratios and associated confidence intervals will be estimated using a Cox Proportional hazards model. Confidence intervals for medians will be estimated using the method of Brookmeyer-Crowley.
Measured: Up to 2 years after randomization. Patients will have MRI on day 90, 180, 270, 360, 540, and 720
Incidence of adverse events
Binary proportions and associated confidence intervals will be estimated.
Measured: Up to 2 years after randomization. Patients will be assessed for adverse event after PCI (for patients on PCI + MRI arm) and at month 3 (all patients)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2019
- Study start4 May 2020
- Primary completion17 Mar 2026
- Study completion15 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Extensive Stage Lung Small Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 668 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Chad G Rusthoven, Principal investigator, SWOG Cancer Research Network
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04155034
- Sponsor's protocol ID
- S1827
- Other IDs
- NCI-2019-05338, S1827, S1827, U10CA180888
- Status last verified
- Jun 2026
- First submitted
- 5 Nov 2019
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Publications
Schneiders FL, Senan S. New strategies for patients with limited-stage small-cell lung cancer. Lancet Respir Med. 2024 Oct;12(10):748-750. doi: 10.1016/S2213-2600(24)00223-6. Epub 2024 Aug 12. No abstract available.
PubMed 39146945
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
- ClinicalTrials.gov ID
- NCT04155034
- Acronym / sponsor ID
- S1827
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 668 participants (estimated)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 4 May 2020 (actual)
- Primary completion
- 17 Mar 2026 (actual)
- Study completion
- 15 Nov 2029 (estimated)
- First posted
- 7 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Detailed description
PRIMARY OBJECTIVE:
- To evaluate whether overall survival (OS) with magnetic resonance imaging (MRI) surveillance alone is not inferior to MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).
SECONDARY OBJECTIVES:
- To compare cognitive failure free survival (CFFS) rate up to 12 months after randomization between the arms.
II. To compare brain-metastasis-free survival between the arms. III. To compare OS between the arms within the subgroups of patients with limited-stage and extensive-stage disease.
IV. To compare cognitive failure free survival (CFFS) rates at the assessment times between the arms.
- To compare the cumulative incidence of cognitive failure with death as a competing risk between the arms.
VI. To compare the frequency and severity of toxicities between the two arms.
ADDITIONAL OBJECTIVE:
- To collect blood for banking.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
ARM II: Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm I (PCI, MRI) | Active comparator | Procedure: Magnetic Resonance Imaging, Radiation: Prophylactic Cranial IrradiationPatients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months. |
| Arm II (MRI) | Experimental | Procedure: Magnetic Resonance ImagingPatients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (25 listed)
- Patient must have a histologically confirmed diagnosis of small-cell lung cancer (SCLC)
- Patient must have an MRI of the brain performed within 28 days prior to registration documenting no evidence of brain metastases or leptomeningeal disease. Patient also must not have a history of brain metastases or leptomeningeal disease
- Immunotherapy concurrent with and/or adjuvant to first-line therapy is allowed at the discretion of the treating physician. Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including stereotactic body radiation therapy [SBRT] for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection; thoracic radiation in addition to definitive surgical resection is allowed at the discretion of the treating physician, but is not required. Patients with extensive-stage (ES)-SCLC must have completed platinum-based chemotherapy either with or without thoracic radiotherapy at the discretion of the treating physician
- All adverse events from prior treatment must have resolved to =< grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) prior to randomization
- Patient must have had a response to first-line therapy and no evidence of progression in opinion of the treating investigator. Systemic imaging (computed tomography [CT] or positron emission tomography [PET]/CT including the chest and abdomen) must be performed within 28 days prior to randomization
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance ImagingAlso: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRIUndergo MRI | Procedure or surgery | Arm I (PCI, MRI), Arm II (MRI) |
| Prophylactic Cranial IrradiationAlso: PCIUndergo PCI | Radiation | Arm I (PCI, MRI) |
Primary outcome
Overall survival (OS)
Time frame: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization
Will evaluate OS with magnetic resonance imaging (MRI) surveillance alone and MRI surveillance combined with prophylactic cranial irradiation (PCI) for the treatment of small cell lung cancer (SCLC).
6 secondary outcomes
Cognitive failure-free survival (CFFS)
Time frame: Baseline to first neurocognitive failure CF or death due to any cause, assessed up to 12 months after randomization
CFFS rate
Time frame: Baseline to first neurocognitive failure CF or death due to any cause, assessed at 90, 180, 270, 360, 540, and 720 days after randomization
Cumulative incidence of cognitive failure
Time frame: Neurocognitive function test will be assessed at 90, 180, 270, 360, 540, and 720 days after randomization
OS in an "as-treated" analysis
Time frame: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization. Patients will be seen at day 90, 180, 270, 360, 540, and 720
Brain metastases-free survival (BMFS)
Time frame: Up to 2 years after randomization. Patients will have MRI on day 90, 180, 270, 360, 540, and 720
Incidence of adverse events
Time frame: Up to 2 years after randomization. Patients will be assessed for adverse event after PCI (for patients on PCI + MRI arm) and at month 3 (all patients)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Derived from this study: PubMed 39146945Schneiders FL, Senan S. New strategies for patients with limited-stage small-cell lung cancer. Lancet Respir Med. 2024 Oct;12(10):748-750. doi: 10.1016/S2213-2600(24)00223-6. Epub 2024 Aug 12. No abstract available.
Related trials for Extensive Stage Lung Small Cell Carcinoma
Active, not recruitingPhase 3
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
RecruitingPhase 2
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Extensive-stage Small-cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
RecruitingPhase 2
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Small Cell Lung Cancer, SCLC
Not yet recruitingPhase 2
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chad G Rusthoven principal investigator
SWOG Cancer Research Network
446 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Magnetic Resonance Imaging and Prophylactic Cranial Irradiation in people with Extensive Stage Lung Small Cell Carcinoma and Limited Stage Lung Small Cell Carcinoma, run by SWOG Cancer Research Network at 446 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 25 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 446 sites in United States, Canada, Chile, Colombia, Mexico and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (OS) (time frame: From the date of registration to date of death due to any cause, assessed up to 2 years after randomization). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04155034, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.